MX346095B - Nuevas imidazol-aminas como moduladores de la actividad de cinasas. - Google Patents

Nuevas imidazol-aminas como moduladores de la actividad de cinasas.

Info

Publication number
MX346095B
MX346095B MX2014002832A MX2014002832A MX346095B MX 346095 B MX346095 B MX 346095B MX 2014002832 A MX2014002832 A MX 2014002832A MX 2014002832 A MX2014002832 A MX 2014002832A MX 346095 B MX346095 B MX 346095B
Authority
MX
Mexico
Prior art keywords
modulators
kinase activity
novel imidazole
imidazole amines
amines
Prior art date
Application number
MX2014002832A
Other languages
English (en)
Other versions
MX2014002832A (es
Inventor
Bankston Donald
Qiu Hui
R Huck Bayard
Chen Xiaoling
Xiao Yufang
Lan Ruoxi
Celeste Deselm Lizbeth
Neagu Constantin
Charles Victor Jones Christopher
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2014002832A publication Critical patent/MX2014002832A/es
Publication of MX346095B publication Critical patent/MX346095B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

La invención proporciona nuevos compuestos de imidazol-amina de acuerdo a la fórmula (I) y Fórmula (II), su elaboración y uso para el tratamiento de enfermedades hiperproliferativas tal como cáncer.
MX2014002832A 2011-09-12 2012-09-12 Nuevas imidazol-aminas como moduladores de la actividad de cinasas. MX346095B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161533601P 2011-09-12 2011-09-12
PCT/US2012/054900 WO2013040059A1 (en) 2011-09-12 2012-09-12 Novel imidazole amines as modulators of kinase activity

Publications (2)

Publication Number Publication Date
MX2014002832A MX2014002832A (es) 2014-05-27
MX346095B true MX346095B (es) 2017-03-07

Family

ID=46881179

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002832A MX346095B (es) 2011-09-12 2012-09-12 Nuevas imidazol-aminas como moduladores de la actividad de cinasas.

Country Status (25)

Country Link
US (2) US9145392B2 (es)
EP (1) EP2755965B1 (es)
JP (1) JP5964974B2 (es)
KR (1) KR101995605B1 (es)
CN (1) CN104080782B (es)
AU (1) AU2012308696B2 (es)
BR (1) BR112014005554A2 (es)
CA (1) CA2844830C (es)
DK (1) DK2755965T3 (es)
EA (1) EA025098B1 (es)
ES (1) ES2644536T3 (es)
HK (1) HK1201825A1 (es)
HR (1) HRP20171554T1 (es)
HU (1) HUE035019T2 (es)
IL (1) IL231383A (es)
LT (1) LT2755965T (es)
MX (1) MX346095B (es)
NO (1) NO2791461T3 (es)
PL (1) PL2755965T3 (es)
PT (1) PT2755965T (es)
RS (1) RS56534B1 (es)
SG (2) SG2014009278A (es)
SI (1) SI2755965T1 (es)
WO (1) WO2013040059A1 (es)
ZA (1) ZA201401013B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2755958T (lt) * 2011-09-12 2017-11-10 Merck Patent Gmbh Aminopirimidino dariniai, skirti naudoti kaip kinazės aktyvumo moduliatoriai
AU2013333938A1 (en) 2012-10-16 2015-04-09 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
JP6280130B2 (ja) 2012-11-16 2018-02-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ キナーゼ活性のモジュレーターとしての新規イミダゾール−ピペリジニル誘導体
EP2970201B1 (en) 2013-03-11 2019-06-19 Merck Patent GmbH 6-[4-(1h-imidazol-2-yl)piperidin-1-yl]pyrimidin-4-amine derivatives as modulators of kinase activity
SG11201605121VA (en) 2014-02-11 2016-07-28 Merck Patent Gmbh Pyrimidine imidazole amines as modulators of kinase activity
JP6529085B2 (ja) 2014-04-18 2019-06-12 武田薬品工業株式会社 複素環化合物
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
KR20200093159A (ko) 2019-01-28 2020-08-05 주식회사 링크모션 스마트 팜 모듈 구조물
TW202128675A (zh) 2019-12-06 2021-08-01 美商維泰克斯製藥公司 作為鈉通道調節劑之經取代四氫呋喃
US11866421B2 (en) 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
EP1615906A1 (en) 2003-04-03 2006-01-18 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
JP2007507531A (ja) 2003-09-30 2007-03-29 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
JP4800216B2 (ja) 2003-10-24 2011-10-26 エグゼリクシス， インコーポレイテッド ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法
AU2004295061B2 (en) 2003-11-21 2008-11-20 Novartis Ag 1H-imidazoquinoline derivatives as protein kinase inhibitors
DE602004024115D1 (de) 2003-12-09 2009-12-24 Us Gov Health & Human Serv Verfahren zur unterdrückung einer immunantwort oder zur behandlung von proliferativen erkrankungen
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
US7994172B2 (en) 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
US20080124384A1 (en) * 2005-01-19 2008-05-29 Blum Charles A Heteroaryl Substituted Piperazinyl-Pyridine Analogues
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
WO2006136821A1 (en) 2005-06-22 2006-12-28 Astex Therapeutics Limited Pharmaceutical compounds
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
DK2396307T3 (en) 2009-02-11 2015-01-12 Merck Patent Gmbh NOVEL AMINO-azaheterocyclic carboxamides
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
WO2012016001A1 (en) 2010-07-29 2012-02-02 Merck Patent Gmbh Cyclic amine azaheterocyclic carboxamides
MX355325B (es) 2010-11-24 2018-04-16 Merck Patent Gmbh Quinazolincarboxamida azetidinas.

Also Published As

Publication number Publication date
LT2755965T (lt) 2017-11-10
AU2012308696B2 (en) 2017-04-27
RS56534B1 (sr) 2018-02-28
EP2755965A1 (en) 2014-07-23
WO2013040059A1 (en) 2013-03-21
US20140343029A1 (en) 2014-11-20
CA2844830C (en) 2019-09-10
EP2755965B1 (en) 2017-07-26
PT2755965T (pt) 2017-11-02
PL2755965T3 (pl) 2018-01-31
HRP20171554T1 (hr) 2017-11-17
CN104080782A (zh) 2014-10-01
MX2014002832A (es) 2014-05-27
AU2012308696A1 (en) 2014-02-27
US20160000785A1 (en) 2016-01-07
NO2791461T3 (es) 2018-07-21
JP2014531436A (ja) 2014-11-27
ES2644536T3 (es) 2017-11-29
EA201400339A1 (ru) 2014-08-29
SG10201606301YA (en) 2016-09-29
CN104080782B (zh) 2016-06-01
KR20140063694A (ko) 2014-05-27
EA025098B1 (ru) 2016-11-30
DK2755965T3 (en) 2017-09-25
IL231383A (en) 2017-11-30
HK1201825A1 (zh) 2015-09-11
CA2844830A1 (en) 2013-03-21
US9145392B2 (en) 2015-09-29
IL231383A0 (en) 2014-04-30
KR101995605B1 (ko) 2019-07-02
JP5964974B2 (ja) 2016-08-03
SI2755965T1 (sl) 2017-12-29
ZA201401013B (en) 2018-07-25
HUE035019T2 (en) 2018-03-28
BR112014005554A2 (pt) 2017-03-21
SG2014009278A (en) 2014-07-30

Similar Documents

Publication Publication Date Title
MX2014002832A (es) Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
MX2014002836A (es) Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
PH12017502141A1 (en) Compounds and their methods of use
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
MX2012001419A (es) Compuestos biciclicos novedosos de urea.
MD20150091A2 (ro) Compuşi antivirali
AU2012324803A8 (en) (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
MX2013010898A (es) Novedoso derivados de la pirimidina.
MX2015000129A (es) Derivados de pirimidin pirazolilo.
MY160468A (en) Novel amino azaheterocyclic carboxamides
MX2013003309A (es) Compuestos de benzamida sustituidos.
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
MX344302B (es) Compuestos de quinazolina sustituidos con alquino y metodos uso.
GEP201706690B (en) Novel process for making compounds for use in treatment of cancer
MX343377B (es) Carboxamidas azaheterocilcicas de amina ciclica.
PH12015501038A1 (en) Inhibitors of iap
WO2014086453A8 (en) Azaheterobicyclic compounds
SG10201900954SA (en) Heterocycles as Modulators of Kinase Activity
MX2014007364A (es) Nuevas carboxamidas heterociclicas como modulares de la activadad de cinasas.
MX2016010268A (es) Pirimidinimidazolaminas como modulares de actividad de cinasa.
MX2014009084A (es) Derivados de pirimidooxazocina como inhibidores de mtor.
EA033160B1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази

Legal Events

Date Code Title Description
FG Grant or registration